课题基金 / 基金详情

项目摘要

项目成果

MARKUS KALKUM的其他基金

相似基金

相关文献

中文摘要
翻译
该提案的目标是开发新的生物化学方法和装置,用于阿摩尔检测 肉毒杆菌神经毒素(BoNT)的所有七种血清型和亚型。根据初步数据,我们 假设产生抗荧光和生物发光底物是可行, 非BoNT蛋白水解切割,但可被BoNT快速激活。建议的具体目标 研究内容包括:1)开发BoNT血清型A至G的新型荧光底物。这些底物 将通过具有蛋白原性和非蛋白原性氨基酸的肽文库来设计, 选择对非BoNT蛋白酶的抗性和BoNT的高效切割。我们将测试ALISSA 在血清、实体器官提取物、灌肠和粪便的各种BoNT加标样品中使用这些新底物 标本以及各种食物。2)肉毒杆菌发光蛋白底物的研制 毒素我们正在提议对重组荧光素酶蛋白的变异体进行基因工程改造, 由肉毒杆菌毒素的金属蛋白酶活性介导的特异性裂解反应激活。 将为肉毒杆菌毒素的所有七种血清型(A至G)创建发光底物。我们还将 生物发光检测,其发射多个波长的光,用于多路同时检测更多的 每个样本不止一种血清型。3)应用现有和新型BoNT ALISSA测量毒素 在动物血清和器官中的分布。与美国农业部的Luisa Cheng博士合作 在加利福尼亚州奥尔巴尼的农业中,我们将利用BoNT ALISSA来测量系统含量和组织 在亚致死BoNT中毒小鼠中的分布。我们的目标是确定药代动力学和药型依赖性 胃肠外或口服中毒后器官中的毒素分布。 此外,与Intrinsic Bioprobes的Nedelkov博士和Precision的Chris Myatt博士合作, 我们将开发和测试全自动化设备,这些设备将利用我们的新方法, 以阿托摩尔灵敏度定量检测BoNT。BoNT ALISSA技术将适用于 转化成由普通液体处理机器人使用的单片微柱形式。由此产生的台式机 仪器还将包括一个高灵敏度、低成本的基于波导的光学读出器 系统我们的检测系统将用复杂的生物基质进行测试和验证,如血清, 固体器官和食物提取物以及临床样品(在加州的Stephen Arnon博士实验室 公共卫生部)。
英文摘要
The goal of this proposal is to develop novel biochemical methods and devices for the attomolar detection of all seven serotypes and subtypes of botulinum neurotoxin (BoNT). Based on our preliminary data, we hypothesize that it is feasible to generate both fluorescent and bioluminescent substrates that are resistant to non-BoNT proteolytic cleavage, but can rapidly be activated by BoNTs. The specific aims of the proposed research are: 1) Development of novel fluoroaenic substrates for BoNT serotypes A to G. These substrates will be designed through peptide libraries with proteinogenic and non-proteinogenic amino acids and will be selected for resistance to non-BoNT proteases and highly efficient cleavage by BoNTs. We will test ALISSAs with those novel substrates in various BoNT-spiked samples of serum, solid organ extracts, enema and stool specimens as well as a variety of foods. 2) Development of a luminogenic protein substrate for botulinum toxin. We are proposing to genetically engineer variants of recombinant luciferase proteins that become activated by specific cleavage reactions mediated by the metalloprotease activity of botulinum toxin. Luminescent substrates will be created for all seven serotypes (A to G) of botulinum toxin. We will also bioluminescent assays that emit light at multiple wavelenght for multiplexed simultaneous detection of more than one serotype per sample. 3) Application of existing and novel BoNT ALISSAs to measure toxin distribution in animal sera and organs. In collaboration with Dr. Luisa Cheng at the U.S. Department for Agriculture in Albany, CA, we will utilize BoNT ALISSA to measure the systemic content and tissue distribution in sub-lethally BoNT-intoxicated mice. Our goal is to determine pharmacokinetics and serotypedependent toxin distributions in organs following parenteral or oral intoxication. Furthermore, in collaboration with Dr. Nedelkov at Intrinsic Bioprobes and with Dr. Chris Myatt at Precision Photonics we will develop and test fully automated devices that will utilize our novel methodology for the quantitative detection of BoNTs at attomolar sensitivity. The BoNT ALISSA technology will be adapted into into a monolithic microcolumn format to be utilized by common liquid handling robots. The resulting benchtop instrumentation will also incorporate a highly sensitive, and inexpensive wave-guide-based optical readout system. Our assay system will be tested and validated with complex biological matrices such as serum, solid organ and food extracts as well as clinical samples (at Dr. Stephen Arnon's laboratory at the California Department for Public Health).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diagnostic assay systems for Botulinum Neurotoxins
Diagnostic assay systems for Botulinum Neurotoxins
Fluorescent and bioluminescent assays for botulinum neurotoxin
  • 批准号:
    8260257
  • 项目类别:
  • 资助金额:
    $40.35万
  • 财政年份:
    2011
  • 负责人:
    MARKUS KALKUM
  • 依托单位:
Diagnostic assay systems for Botulinum Neurotoxins
海外基金